Skip to content

Skin

Skincare on feminizing HRT, with a focus on the specific shifts estrogen plus DHT suppression produces and how a routine should adapt across the first two years and beyond. The dominant skin signal on transfeminine HRT is sebum suppression within the first year, driven by DHT collapse rather than estrogen action directly — pores shrink visibly, oil-driven acne usually improves, and a new dryness pattern emerges six to eighteen months in as the previously oily face transitions toward balanced or dry. Subcutaneous fat thickens slowly over one to two years, softening contours but not reversing prior photoaging.

This page covers face and body skin, the active ingredients that matter, and the targeted concerns most likely to show up on HRT. It does not cover hair removal — see Hair Removal for laser and electrolysis. For makeup over a working skincare base, see the Makeup hub. For the hormonal mechanisms behind the skin changes described here, see Anti-Androgens and Estrogens. For broader context on long-term HRT effects, see Cardiovascular Health. The Presentation Hub links the rest of this section.

Active ingredient first, brand last

Skincare marketing sells brands; skincare science describes molecules. A working routine is defined by the active ingredients in each product (the surfactant in your cleanser, the humectant–emollient–occlusive ratio in your moisturizer, the UV filters in your sunscreen, the percentage and form of any active serum). Brand and packaging do not change what those molecules do. The drugstore aisle and the luxury counter draw from the same supply chain.

Skin type, and how HRT shifts it

Skin type categorization is approximate but useful for product selection. The five working categories — normal, dry, oily, combination, sensitive — are behavioural descriptions of sebum output, transepidermal water loss (TEWL), and reactivity, not fixed traits. Type shifts predictably on feminizing HRT and should be reassessed every six to twelve months in the first two years.

  • Normal — balanced sebum, minimal flaking or shine, tolerates most ingredients. Skin feels comfortable one to two hours after washing, no tight or greasy sensation, pore visibility moderate.
  • Dry — low sebum, often elevated TEWL, visible flaking or tightness. Skin feels tight after cleansing; fine flakes around nasolabial folds or forehead; makeup catches on dry patches. Tends toward sensitivity over time as barrier function degrades.
  • Oily — high sebum output, visible shine within one to two hours of cleansing, enlarged pores especially in the T-zone, predisposed to comedonal and inflammatory acne. Blotting paper picks up oil from forehead, nose, and chin within hours; midday shine is reliable.
  • Combination — oily T-zone (forehead, nose, chin) with normal-to-dry cheeks. The most common adult pattern and the one most pre-HRT trans women report. Often managed by zone-targeted product use rather than treating the whole face the same.
  • Sensitive — reactive to fragrance, alcohols, acids, or mechanical irritation; tends toward redness, stinging, or transient erythema. Sensitivity overlays the other types — sensitive-dry and sensitive-combination are common; sensitive-oily exists but is less common.

How HRT shifts type

Sebum production is androgen-driven, with DHT the dominant driver via 5α-reductase activity in pilosebaceous units. Suppressing serum testosterone below ~50 ng/dL typically reduces sebum output by 35–60% within one to six months of adequate suppression — measurable on sebumeter studies in cyproterone- and GnRH-suppressed populations. Giltay & Gooren 2000 documented sebum production falling to cisgender-female ranges within months of cross-sex hormone initiation, with corresponding visible reduction in shine and pore prominence.

The typical trajectory: pre-HRT oily or combination skin transitions to combination or normal in months three to six, then toward dry-normal or dry by twelve to eighteen months as the sebum that was masking baseline barrier function disappears. Trans women whose pre-HRT skin was already dry tend toward more pronounced dryness and sensitivity. Pre-HRT normal or combination skin lands closer to balanced or mildly dry.

Type stabilizes by year two or three in most cases. After that, age-related drift toward drier skin continues at the same rate as in cisgender populations. The pre-HRT "my skin is oily" routine is almost always wrong by month twelve and is the single most common cause of barrier issues in the first two years on HRT.

What HRT does to skin

The trans-specific anchor for this page. The mechanisms below run on overlapping timelines; expect most of them to express within the first two years on stable HRT, with pigmentation and barrier shifts continuing to evolve afterward.

Sebum reduction (months 1–6)

Adequate androgen suppression — total T < 50 ng/dL or DHT below the lower quartile of the cisgender-female reference range — produces measurable sebum drop within the first one to three months and continues evolving through month six. Visible correlates: less midday shine, blotting papers picking up less oil, foundation sitting differently, scalp hair staying clean longer. Wierckx 2014 (ENIGI) documented self-reported "less oily skin" in roughly 70% of transfeminine patients within six months. Zouboulis 2007 frames the underlying mechanism — sebaceous glands are direct androgen targets, with DHT the dominant ligand at the local 5α-reductase isoforms expressed in pilosebaceous units.

Pore size

Pores are not muscles and don't "open" or "close," but visible pore size correlates strongly with sebum content and with the size of the pilosebaceous infundibulum. As sebum production drops, pores empty, and visible diameter shrinks. The effect is most pronounced on the nose and central cheeks. It is real but bounded — pore size also has genetic and photoaging components that HRT does not address. Existing pore stretching from chronic comedone formation or sun damage is permanent.

Subcutaneous fat thickening (1–2 years)

Estrogen drives subcutaneous fat redistribution and slow accumulation. The facial subcutaneous layer thickens gradually over twelve to twenty-four months, softening bony contours, filling tear troughs and nasolabial folds modestly, and producing the characteristic "softer face" outcome of HRT. Effect size varies enormously by starting body composition, age at HRT start, and genetics. Adolescent-onset patients show essentially cisgender-female facial fat distribution; adult-onset patients see softening but rarely a complete shift. The change is gradual enough that month-over-month photos are usually needed to see it.

New dryness pattern (6–18 months)

The most-reported skin complaint at the six-to-eighteen-month mark is "my skin feels different — tight, sometimes flaky, especially after washing." This is the sebum-loss baseline becoming visible. Pre-HRT, sebum was occluding the stratum corneum and masking elevated TEWL; with sebum reduced, the underlying barrier state is exposed. Most patients adapt by switching to a richer moisturizer and gentler cleanser. A minority develop persistent dry-skin patterns requiring ceramide-rich layering and humidifier use.

Acne course

Acne trajectory on HRT is bidirectional in the short term and typically improving in the long term:

  • Early HRT (months 0–6) — can trigger an adolescent-style flare. Testosterone fluctuations during titration produce sebum surges before suppression is established, and patients on subtherapeutic estrogen with inadequate androgen blockade can paradoxically have higher free T than baseline.
  • Stable HRT (year 1+) — consistently improves comedonal and inflammatory acne in patients whose pre-HRT acne was androgen-driven (most adult acne in AMAB people). Hormonal cystic acne and rosacea-pattern eruptions respond less reliably.

Sensitivity increase

A meaningful minority — roughly 20–40% in informal community surveys, with no formal prevalence data — develop new sensitivity to fragrance, retinoids, acids, or mechanical exfoliation in the first six to eighteen months. The mechanism is uncertain; candidates include thinner stratum corneum from sebum loss, estrogen-mediated shifts in inflammatory signalling, and unmasking of pre-existing barrier dysfunction. The practical implication is that products tolerated pre-HRT may stop being tolerated, and ramping up actives more cautiously than published protocols suggest is reasonable.

Skin barrier changes

The stratum corneum becomes thinner and more reactive on long-term HRT, mirroring cisgender-female skin behaviour. Barrier resilience to physical insult (cold, wind, harsh cleansers, mechanical scrubs) decreases. Recovery time after barrier disruption lengthens — what cleared in three days pre-HRT may take five to seven days on stable HRT.

Sun damage does not reverse

Photoaging — solar elastosis, dyspigmentation, fine and coarse wrinkles, actinic keratoses — is cumulative and does not reverse on HRT. Patients sometimes expect facial feminization from estrogen to undo decades of UV exposure; it won't. Fat-pad thickening softens contours but does not address dermal collagen damage, elastosis, or solar lentigines. Anti-aging on HRT requires the same interventions as in cisgender populations: SPF, retinoids, antioxidants, and procedural treatments where indicated.

Pigmentation changes

Hormonal shifts can trigger hyperpigmentation, most commonly a melasma-like pattern on cheeks, upper lip, and forehead. Estrogen and progesterone both contribute to melasma in cisgender pregnancy and oral contraceptive use; the same mechanism applies to transfeminine HRT, particularly in higher-Fitzpatrick skin types (III–VI). Onset is variable — anywhere from three months to three years. Sun exposure is the dominant trigger; melasma responds to UV protection, hydroquinone, tranexamic acid (oral or topical), azelaic acid, and gentle exfoliation. Post-inflammatory hyperpigmentation from acne or picking is a separate process and is more responsive to standard treatment.

Basic routine framework

A working routine has three obligatory steps and one strongly recommended addition. Everything beyond is optimization.

Cleanse

Cleansers remove sebum, sweat, environmental debris, and product residue. Surfactant chemistry matters more than brand:

  • Sulfates (sodium lauryl sulfate, sodium laureth sulfate) — strong, can strip lipids from compromised barriers. Acceptable in body washes; usually too aggressive for face wash on shifting transfeminine skin.
  • Betaines (cocamidopropyl betaine) — milder amphoteric surfactants; common in "gentle" cleansers.
  • Glucosides (decyl glucoside, coco-glucoside) — non-ionic, very mild; preferred for sensitive or post-active skin.
  • Syndets (synthetic detergent bars, "beauty bars") — pH-balanced alternatives to true soap; tolerable for body and face.
  • True soap — alkaline (pH 9–10), strips skin lipids, raises stratum corneum pH, generally inappropriate for facial skin on HRT.

Skin's native pH is approximately 5.5; cleansers in the pH 4.5–6 range preserve the acid mantle and the lipid bilayer of the stratum corneum. Cleanser pH is rarely listed on packaging but is searchable for most products.

Morning cleansing is optional — for dry or sensitive skin, water alone or a micellar wipe is often sufficient. Evening cleansing is mandatory: removes sebum, sweat, sunscreen, and particulate. Double cleansing (oil-based cleanser followed by water-based cleanser) is appropriate on days with heavy sunscreen, makeup, or sebum buildup. Once-daily cleansing with a single gentle cleanser is fine for normal-to-dry skin.

Moisturize

Moisturizers combine three functional categories:

  • Humectants — bind water from environment and dermis to stratum corneum. Glycerin, hyaluronic acid (HA), urea (low concentrations 5–10%), panthenol (provitamin B5), sodium PCA. Work better in humid environments; in dry climates, can pull water out of skin if not occluded.
  • Emollients — fill gaps between corneocytes, smooth texture, restore feel. Ceramides (1, 3, 6-II especially), squalane, fatty alcohols (cetyl, stearyl, cetearyl), plant oils (jojoba, sunflower, rosehip), shea butter fractions.
  • Occlusives — physical barrier reducing TEWL. Petrolatum (most effective, ~99% TEWL reduction), dimethicone, mineral oil, lanolin, beeswax. Petrolatum is non-comedogenic despite reputation.

Match composition to current skin type. Oily and combination skin tolerates humectant-dominant gels and lotions; dry and post-HRT skin needs all three layers — humectant plus emollient plus occlusive — most reliably delivered in cream form.

Apply to damp skin within sixty seconds of cleansing or showering. Humectants need water to bind; applying to fully dry skin draws moisture from the dermis instead of trapping ambient water.

Sun protection

Daily broad-spectrum SPF 30+ is the single highest-evidence anti-aging intervention. Hughes 2013 — randomized trial, n=903, 4.5 years — showed daily sunscreen users had no detectable photoaging progression versus visible progression in discretionary users, with effect size larger than any topical treatment.

SPF measures UVB protection (sunburn, direct DNA damage, the dominant carcinogenic wavelength). Broad-spectrum designation requires UVA protection sufficient to scale with SPF — important because UVA penetrates deeper, drives photoaging, and reaches skin through window glass and clouds.

Filter chemistry:

  • Mineral (physical) — zinc oxide, titanium dioxide. Sit on skin surface, scatter and absorb UV. Photostable, broad-spectrum (zinc especially), low irritation. White cast on darker skin types is the main cosmetic issue; modern micronized and tinted formulations partially solve this.
  • Chemical (organic) — avobenzone, octinoxate, octocrylene, homosalate, octisalate, oxybenzone, and modern UVA-effective filters. Absorb UV and dissipate as heat. Avobenzone is the dominant US UVA filter but degrades in sun without stabilizers.
  • Modern UVA filters — Tinosorb S, Tinosorb M, Mexoryl SX, Mexoryl XL, Uvinul A Plus. Available in EU, Asia, and Mexico but not the US; provide superior UVA protection and are photostable. US sunscreen filter regulation lags significantly; patients seeking best UVA protection often source international formulations.

Reapply every two hours of active sun exposure, after swimming or heavy sweating, and after wiping the face. Indoor day with no window exposure: a single morning application suffices. Cumulative dose matters; daily consistency outperforms occasional heavy use.

Active ingredients

The centrepiece of any optimization. The table below covers the evidence-backed actives in roughly increasing complexity. Frame: pick one or two to start, ramp slowly, and only add a third once the first two are stable.

Ingredient What it does When to use Cautions
Retinoids (tretinoin, adapalene, retinol) Bind RAR/RXR receptors; drive keratinocyte differentiation, increase dermal collagen synthesis, normalize follicular keratinization, reduce melanogenesis. Nightly, on dry skin twenty minutes after cleansing. The single highest-evidence anti-aging and acne ingredient. Photosensitizing — pair with daily SPF. Expect "retinization" (flaking, redness) for 2–6 weeks. Pregnancy contraindication — see warning below.
Vitamin C (L-ascorbic acid 10–20%) Antioxidant, photoprotection adjunct, brightening, modest collagen synthesis stimulus. Works at pH < 3.5. AM under sunscreen for photoprotection synergy, or PM if sunscreen interaction stings. Unstable — oxidizes to brown on light/air exposure; replace when colour shifts. Stinging on compromised barrier is common, not a sign of efficacy.
Niacinamide (vitamin B3, 2–10%) Barrier support via increased ceramide and free fatty acid synthesis; sebum modulation; anti-inflammatory; modest pigmentation improvement. AM or PM, layered with almost anything. The most reliable second active after a retinoid. Very well tolerated. Some sources warn against high-concentration vitamin C layering; clinically minor.
AHAs (glycolic, lactic, mandelic) Water-soluble exfoliants; loosen corneocyte adhesion, smooth texture, fade superficial pigmentation. Glycolic deepest, mandelic gentlest. 2–3× per week PM, on nights without retinoid. Glycolic 5–10% on resilient skin; mandelic for sensitive or Fitzpatrick IV–VI. Photosensitize for ~1 week post-application; daily SPF mandatory. Don't layer with retinoids on the same night unless well-tolerated.
BHA (salicylic acid 0.5–2%) Oil-soluble; penetrates sebum-filled pores, decongests comedones, anti-inflammatory. Daily-to-2–3× weekly for oil-driven comedonal acne; less effective for hormonal cystic acne. Aspirin allergy is a relative contraindication. Drying at higher concentrations.
PHAs (gluconolactone, lactobionic acid) Larger-molecule hydroxy acids; slower surface exfoliation than AHAs; humectant-leaning structure. Sensitive skin or as a step-down from AHA tolerance issues. Generally well-tolerated; effect size smaller than AHAs.
Azelaic acid (10% OTC, 15–20% Rx) Anti-inflammatory, anti-bacterial against C. acnes, tyrosinase inhibitor, anti-keratinizing. Inflammatory acne, rosacea, melasma, post-inflammatory hyperpigmentation. Pairs with retinoids; pregnancy-compatible. Tingling on application is common and self-limiting. Slow visible response (8–12 weeks).
Benzoyl peroxide (2.5–5%) Antibacterial against C. acnes; mildly comedolytic. First-line topical for inflammatory acne. Combines well with topical antibiotics to slow resistance. Bleaches fabrics, hair, towels. Drying. Inactivates tretinoin if applied simultaneously — alternate AM/PM if combining.
Hydroquinone (2% OTC where allowed, 4% Rx) Tyrosinase inhibitor; gold-standard topical depigmenting agent. Melasma, post-inflammatory hyperpigmentation, solar lentigines. Cycle 3 months on, 3 months off. Risk of exogenous ochronosis with prolonged uninterrupted use, especially in higher-Fitzpatrick skin. Banned or restricted in EU/Japan.
Tranexamic acid (oral 250 mg BID, topical 3–5%) Inhibits plasminogen activation in keratinocytes; suppresses melasma at the upstream inflammatory step. Refractory melasma when topicals alone are insufficient. Oral form has VTE risk — relevant for transfeminine patients on oral estrogen; coordinate with prescriber. Topical safer but slower.
Peptides (Matrixyl, copper peptides) Short amino-acid sequences marketed for collagen stimulation and barrier support. Optional addition for established routine. Low-risk, modest effect. Limited high-quality clinical evidence; effect sizes small.
Ceramides (1, 3, 6-II) Replenish stratum corneum lipid matrix; restore barrier function. Daily in moisturizer, especially on dry or post-HRT skin. None meaningful. Foundational, not optional.

Retinoids are contraindicated in pregnancy

Topical and oral retinoids — tretinoin, tazarotene, adapalene, isotretinoin — are teratogenic and contraindicated in pregnancy. This is largely irrelevant for transfeminine patients themselves, but matters when sharing skincare with cisgender partners who may be or become pregnant, when prescribing to AFAB patients, and for handling oral isotretinoin under iPLEDGE administrative requirements (which apply regardless of biological pregnancy capacity in the US). Topical adapalene, sometimes treated as the safest of the class, still falls under the contraindication.

Retinoid ramping protocol

Any retinoid — OTC retinol through prescription tazarotene — benefits from slow ramping to manage retinization (the predictable flaking, redness, and dryness phase that lasts two to six weeks).

  1. Start two nights per week.
  2. Increase to alternate nights at week four if tolerated.
  3. Increase to nightly at week eight to twelve if tolerated.
  4. Apply pea-sized amount to dry face, twenty minutes after cleansing.

Persistent burning, eczematous reaction, or severe peeling indicates intolerance; back off frequency or strength. The potency hierarchy from weakest to strongest: retinyl esters → retinol → retinaldehyde → adapalene 0.1–0.3% → tretinoin 0.025–0.1% → tazarotene 0.05–0.1%. Adapalene is the only prescription-strength retinoid available OTC in the US (0.1%) and is a reasonable starting point for most transfeminine patients; tretinoin remains the gold standard for established anti-aging routines.

Targeted concerns

Acne

Treatment ladder, in escalating order:

  1. Topical BPO (benzoyl peroxide) 2.5–5% — antibacterial, mildly comedolytic. First-line for inflammatory acne. Bleaches fabrics; rotate or use rinse-off. Combines well with topical antibiotics to reduce resistance.
  2. Topical salicylic acid 0.5–2% — comedonal acne, blackheads, oily skin.
  3. Topical retinoid (adapalene OTC; tretinoin or tazarotene Rx) — anti-comedonal; foundation of any chronic acne regimen.
  4. Topical antibiotics — clindamycin, erythromycin; always combined with BPO or retinoid to reduce resistance development.
  5. Oral antibiotics — doxycycline 50–100 mg/day or minocycline; three- month course typically. Anti-inflammatory and antibacterial.
  6. Oral isotretinoin — for nodulocystic, scarring, or refractory acne. Definitive treatment for severe acne; iPLEDGE registration required in the US; teratogenic but irrelevant for unfertile transfeminine patients (administrative pregnancy-prevention requirements may still apply). Effective at cumulative dose 120–150 mg/kg.
  7. Hormonal — spironolactone is standard for hormonal acne in cisgender women at 50–200 mg/day. Transfeminine patients are typically already on spironolactone or an alternative anti-androgen as part of HRT, so "adding spironolactone for acne" is double-dosing what is already there. If acne persists on HRT with adequate T suppression, the issue is not androgen exposure; pursue isotretinoin or topical optimization instead. See Anti-Androgens.

Dryness

Layering protocol for stubborn dryness:

  1. Damp skin after cleansing or shower.
  2. Humectant serum (HA, glycerin, panthenol).
  3. Cream moisturizer (humectant + emollient + occlusive).
  4. Optional occlusive layer (petrolatum-based) for severe cases or overnight.

In-shower technique: cooler water, shorter exposure (5–10 min), pat dry incompletely, moisturize within sixty seconds. A bedroom humidifier maintaining 40–60% relative humidity addresses winter and air-conditioned environments.

Sensitivity

Patch test new products on inner forearm or behind ear for three to five days before facial use. Fragrance — both synthetic and "natural" essential oils — is the single most common contact sensitizer in skincare. Simplify to fragrance-free, short-ingredient-list products. If sensitivity emerges on HRT, consider removing one active at a time (typically retinoid first if recently started) to identify the trigger.

Hyperpigmentation

Treatment depends on pattern:

  • Sun-driven (solar lentigines, diffuse photoaging) — SPF, retinoid, vitamin C, time.
  • Post-inflammatory hyperpigmentation (PIH) from acne or picking — same as above plus aggressive acne control; PIH fades over six to twelve months with sun protection.
  • Melasma — recalcitrant; UV protection mandatory; topical hydroquinone 4% (prescription in many countries), tranexamic acid (oral 250 mg twice daily or topical 3–5%), azelaic acid 15–20%, gentle exfoliation, in-office procedures (chemical peels, low-fluence Q-switched laser).

Higher-Fitzpatrick skin types are at higher risk of all pigmentation issues and at higher risk of PIH from procedures themselves; choose interventions conservatively.

Anti-aging

Evidence-weighted hierarchy:

  1. Daily broad-spectrum SPF 30+ — single highest-impact intervention.
  2. Nightly retinoid — second highest-impact; tretinoin 0.025–0.05% is the benchmark.
  3. Antioxidants (vitamin C, vitamin E, ferulic acid) — adjunct, mechanistically supported, modest standalone effect.
  4. Niacinamide, peptides, growth factors — marginal additional benefit.
  5. In-office procedures (chemical peels, microneedling, IPL, laser resurfacing, RF microneedling) — meaningful adjunct for established photoaging that topicals cannot reach.

Everything else (collagen drinks, jade rollers, gua sha, LED masks, "infusion" treatments) ranges from negligible to placebo.

Rosacea

Chronic inflammatory facial dermatosis with vascular, papulopustular, and phymatous subtypes. Hormonal shifts are a recognized trigger; some transfeminine patients develop rosacea on HRT, others find pre-existing rosacea improves. Trigger avoidance is foundational: alcohol, spicy food, heat, sun exposure, hot beverages, exercise-induced flushing, stress. Topical treatment ladder: metronidazole 0.75%, ivermectin 1%, azelaic acid 15%; oral doxycycline 40 mg sub-antimicrobial dose; brimonidine for flushing; vascular laser for telangiectasia. Avoid harsh exfoliants, fragranced products, and high-concentration actives. Mineral sunscreens generally tolerated better than chemical filters in rosacea-prone skin.

Eczema and atopic dermatitis

Pre-existing eczema can shift on HRT — improve, worsen, or change distribution. Mechanism is unclear; estrogen affects Th2 inflammation in cisgender pregnancy and the menstrual cycle, with comparable effects plausible on HRT. Treatment is unchanged from cisgender protocols: barrier repair (ceramide moisturizers, petrolatum), trigger identification, topical steroids for flares, topical calcineurin inhibitors (tacrolimus, pimecrolimus) for steroid-sparing on face, dupilumab or JAK inhibitors for severe refractory cases.

Body skin

Body skin is thicker, lower in sebaceous gland density (except chest and upper back), and lower-priority than facial skin for most patients on HRT. Sebum reduction occurs body-wide but is less visible because baseline output was lower.

Minimum-viable body routine: gentle body wash (avoid sulfate-dominant formulas), moisturize within sixty seconds of toweling off, SPF on exposed areas with prolonged sun exposure. Body lotions with humectant plus emollient combination are appropriate; thicker creams for elbows, knees, hands, heels.

  • Keratosis pilaris (KP) — rough bumps on outer upper arms, thighs, buttocks. Genetic; affects roughly 40% of adults. Treatment: urea 10–20% or salicylic acid 2% leave-on, ammonium lactate 12%, or AHA-based body lotions. Improvement is gradual and requires consistency; KP is not curable, only manageable.
  • Ingrown hairs — common after laser hair removal phases or when shaving body areas. Salicylic acid 2% body lotion, mild glycolic acid (5–10%) toner, exfoliating mitt 2–3× per week. Avoid picking; PIH at ingrown sites is durable. See Hair Removal for removal-modality choice.
  • Leg dryness — disproportionately common on HRT, related to lower sebum and the relatively avascular nature of lower-leg skin. Body cream after showering; petrolatum-based balms for severe winter dryness.
  • Chest acne — a subset of patients develop chest or upper-back acne in the first year of HRT, particularly during titration. Same treatment ladder as facial acne; BPO body wash is an efficient delivery vehicle.

Skincare on a budget

A complete evidence-based routine is achievable under $30 at drugstore prices. The active ingredients matter; brand and packaging do not.

Minimum-viable routine:

  • Gentle facial cleanser with mild surfactant (glucoside, betaine, or syndet bar) — $5–10.
  • Humectant + emollient moisturizer (glycerin + ceramides or fatty alcohols) — $10–15.
  • Broad-spectrum SPF 30+ (mineral or chemical, depending on tolerance) — $8–15.

Categorical examples meeting these criteria are widely available from major drugstore lines (CeraVe, La Roche-Posay, Eucerin, Vanicream — illustrative of the category, not endorsements) at prices below name-brand cosmetic counters. Single-active formulation lines (The Ordinary and similar) offer niacinamide 10%, retinol, salicylic acid, and glycolic acid at $5–10 per product.

Optional additions, in priority order if budget allows:

  1. OTC retinoid (adapalene 0.1%) — $15–20 for a 3–6 month tube.
  2. Vitamin C serum or niacinamide serum — $10–20.
  3. Targeted active for specific concern (azelaic acid, salicylic acid leave-on).

Cost-per-use math favours larger drugstore packaging over small luxury formulations. A $45 4-oz drugstore moisturizer at twice-daily use lasts roughly three to four months; a $95 1-oz luxury moisturizer at the same use rate lasts roughly three to four weeks.

Common mistakes

  • Over-cleansing — twice-daily aggressive cleansing on skin that is no longer oily strips the barrier; once-daily evening cleanse is sufficient for most post-HRT skin.
  • Over-exfoliation — daily AHA/BHA, scrubs, and physical exfoliators combined produce barrier damage masquerading as "purging"; cap chemical exfoliation at 2–3× weekly outside of dedicated short-term peels.
  • Layering too many actives — retinoid plus vitamin C plus AHA plus BHA plus niacinamide plus peptide simultaneously dilutes any single benefit and stacks irritation; one to two actives is sufficient.
  • Treating breakouts harshly — scrubbing, alcohol-based "spot treatments," and aggressive picking worsen PIH and barrier disruption.
  • Skipping moisturizer because oily — sebum and hydration are different; oily-but-dehydrated skin is common and responds to humectant-dominant moisturizer.
  • Skipping sunscreen indoors — UVA penetrates window glass; daily application regardless of indoor or outdoor day is the correct default.
  • Stopping a routine prematurely — retinoids take twelve weeks for early visible effect, six-plus months for substantial collagen response; vitamin C similarly cumulative.

Procedures

In-office procedures complement topical routines for established photoaging, acne scarring, pigmentation, and texture irregularity. Mention without endorsement; consult a dermatologist before any procedural choice.

  • Chemical peels — superficial (glycolic, salicylic, mandelic), medium (TCA, Jessner's), deep (phenol). Address surface texture, mild pigmentation, and superficial acne scarring.
  • Microneedling — controlled mechanical injury triggering wound-healing collagen response; addresses texture, mild scarring, fine lines.
  • Microneedling with radiofrequency — adds RF heat for deeper dermal remodelling; better for moderate acne scarring and skin laxity.
  • IPL (intense pulsed light) — broadband light targeting pigmented and vascular lesions; best for solar lentigines and diffuse redness. Higher- Fitzpatrick skin requires careful settings or alternative modality.
  • Laser resurfacing — fractionated non-ablative (Fraxel) or ablative (CO2, erbium); address established wrinkles, scarring, and photoaging. Significant downtime for ablative.
  • Vascular lasers (PDL, KTP) — telangiectasias, rosacea-related redness.
  • Q-switched and picosecond lasers — pigmentation, including melasma at carefully selected fluences.

Procedural choice depends on skin type (Fitzpatrick I–III tolerate more aggressive interventions), specific concern, and downtime tolerance. Trans- specific note: post-laser-hair-removal patients on HRT have already encountered most laser modalities and may have established preferences about which devices and settings their skin tolerates. See Hair Removal.

See also

Sources

Author-title (cosmetic chemistry references):

  • Baumann L. Cosmetic Dermatology: Principles and Practice. 2nd ed. McGraw-Hill, 2009.
  • Draelos ZD. Cosmetic Dermatology: Products and Procedures. 2nd ed. Wiley-Blackwell, 2015.
  • Barel AO, Paye M, Maibach HI, eds. Handbook of Cosmetic Science and Technology. 4th ed. CRC Press, 2014.